Lexicon Pharmaceuticals (NASDAQ:LXRX) Now Covered by Analysts at StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) in a research note issued on Monday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Several other research firms have also weighed in on LXRX. Leerink Partnrs lowered shares of Lexicon Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, March 5th. Piper Sandler decreased their price objective on shares of Lexicon Pharmaceuticals from $10.00 to $6.00 and set an “overweight” rating on the stock in a research note on Friday, March 7th. HC Wainwright reiterated a “buy” rating and issued a $4.00 target price on shares of Lexicon Pharmaceuticals in a research note on Friday, March 28th. Needham & Company LLC restated a “hold” rating on shares of Lexicon Pharmaceuticals in a research report on Monday, March 3rd. Finally, Leerink Partners reiterated a “market perform” rating and issued a $1.00 price objective (down previously from $2.00) on shares of Lexicon Pharmaceuticals in a research report on Tuesday, March 4th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, Lexicon Pharmaceuticals currently has an average rating of “Hold” and an average price target of $3.67.

Lexicon Pharmaceuticals Stock Up 2.0 %

NASDAQ LXRX opened at $0.51 on Monday. Lexicon Pharmaceuticals has a 1-year low of $0.28 and a 1-year high of $2.45. The company has a market capitalization of $125.53 million, a price-to-earnings ratio of -0.68 and a beta of 1.02. The stock’s 50 day moving average is $0.50 and its two-hundred day moving average is $0.86. The company has a current ratio of 7.45, a quick ratio of 7.43 and a debt-to-equity ratio of 0.56.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings results on Thursday, March 6th. The biopharmaceutical company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.02. Lexicon Pharmaceuticals had a negative return on equity of 107.38% and a negative net margin of 4,109.41%. The business had revenue of $26.55 million for the quarter, compared to analyst estimates of $6.48 million. Equities analysts forecast that Lexicon Pharmaceuticals will post -0.66 earnings per share for the current fiscal year.

Institutional Trading of Lexicon Pharmaceuticals

Several hedge funds have recently modified their holdings of LXRX. Bayesian Capital Management LP bought a new position in Lexicon Pharmaceuticals in the 4th quarter worth approximately $31,000. Wealth Enhancement Advisory Services LLC bought a new stake in shares of Lexicon Pharmaceuticals during the first quarter worth $32,000. RPO LLC acquired a new position in shares of Lexicon Pharmaceuticals during the fourth quarter valued at $33,000. Renaissance Technologies LLC bought a new position in Lexicon Pharmaceuticals in the fourth quarter valued at about $38,000. Finally, Arizona State Retirement System boosted its holdings in Lexicon Pharmaceuticals by 34.4% in the fourth quarter. Arizona State Retirement System now owns 62,976 shares of the biopharmaceutical company’s stock valued at $47,000 after acquiring an additional 16,136 shares during the last quarter. 74.70% of the stock is owned by institutional investors.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.